Physician profile
Lawrence E Feldman
NPI 1871607051
$269.89
in general payments reported to CMS, 2019-2025
19 companies · $89.20 in 2025
The $89.20 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $8.35 · 2021: $73.02 · 2022: $77.63 · 2023: $21.69 · 2025: $89.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $68.49 · Food and Beverage: $42.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $68.49 |
| Food and Beverage | $42.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Merck Sharp & Dohme LLC | $44.29 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.00 | 2022 | |
| Genentech USA, INC. | $24.81 | 2021 | |
| Emd Serono, INC. | $21.69 | 2023 | Tepmetko |
| Tempus Ai, INC | $20.71 | 2025 | Xt Cdx |
| Seagen INC. | $19.87 | 2021 | |
| Deciphera Pharmaceuticals INC. | $18.01 | 2022 | |
| Exelixis INC. | $15.93 | 2022 | |
| Lilly USA, LLC | $11.09 | 2021 |
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.